HTB | HIV i-Base

Global update: 90-day review ended early and cancelled 10,000 grants, millions of people will suffer

Featured CROI 2025: Introduction to this year’s conference 20 March 2025. Related: Conference reports, Conference index, CROI 32 San Francisco 2025.
Featured Impact of US elections and executive orders on global health: waiver covers PEPFAR with restrictions 7 February 2025. Related: Special reports, Treatment access, Treatment advocacy.
CROI 2025: Two bNAbs enable viral suppression off-ART in African women in the FRESH cohort 21 March 2025. Related: Conference reports, Cure-related research, CROI 32 San Francisco 2025.
CROI 2025: Switching to daily fixed-dose doravirine/islatravir: two randomised phase 3 studies 20 March 2025. Related: Conference reports, Antiretrovirals, CROI 32 San Francisco 2025.
CROI 2025: Tecovirimat has no benefit against mpox in STOMP study 18 March 2025. Related: Conference reports, mpox, CROI 32 San Francisco 2025.
CROI 2025: Ensitrelvir significantly reduces risk of developing COVID-19 after household exposure 18 March 2025. Related: Conference reports, COVID-19, CROI 32 San Francisco 2025.
CROI 2025: N6LS: 4-monthly injectable bNAb with monthly injectable cabotegravir 18 March 2025. Related: Conference reports, Antiretrovirals, CROI 32 San Francisco 2025.
Summary of Australian guidelines for anal cancer screening in people living with HIV 18 March 2025. Related: Guidelines.
CROI 2025: Reducing Biktarvy from daily to only once, twice or three times a week 17 March 2025. Related: Conference reports, Antiretrovirals, Treatment strategies, CROI 32 San Francisco 2025.
CROI 2025: Potential for once-yearly lenacapavir injections 16 March 2025. Related: Conference reports, Antiretrovirals, PK and drug interactions, HIV prevention and transmission, CROI 32 San Francisco 2025.
CROI 2025: Delegates send open letter to protest US cuts 12 March 2025. Related: Conference reports, Treatment advocacy, CROI 32 San Francisco 2025.
CROI 2025: RIO study: Dual-bNABs keep viral load undetectable off-ART – plus a potential first case of vaccine-like HIV remission 12 March 2025. Related: Conference reports, Cure-related research, CROI 32 San Francisco 2025.
CROI 2025: Stand Up For Science rally against Trump funding freeze 9 March 2025. Related: Conference reports, Treatment advocacy, CROI 32 San Francisco 2025.
Jay Bhattacharya is proposed to head the US NIH which would further wreck global science 7 March 2025. Related: Treatment advocacy.
Future meetings and webinars 2025 1 March 2025. Related: Future meetings.
Global update: 90-day review ended early and cancelled 10,000 grants, millions of people will suffer 1 March 2025. Related: Special reports, Treatment access.
Responses to the UK government slashing international aid by 40% 26 February 2025. Related: Treatment access, Treatment advocacy.
Deleted words from official documents: LGBTQ, diversity, inclusion, transgender 26 February 2025. Related: Treatment access, Treatment advocacy.
Country update from Nigeria: current impact on HIV services 22 February 2025. Related: Special reports, Treatment access.
Semaglutide reduces alcohol and cigarette use in a randomised phase 2 study 12 February 2025. Related: Weight, diabetes, metabolic complications, Coinfections and complications.
News and resources linked to changes in US policy on international aid 7 February 2025. Related: Special reports.
IAS public letter: Why HIV could be poised for a monumental comeback 6 February 2025. Related: Treatment access, On the web.
Lenacapavir for PrEP submitted to EMA for EU and global use 4 February 2025. Related: Antiretrovirals, HIV prevention and transmission.
New mpox vaccination sites open in the UK 3 February 2025. Related: mpox.
Africa CDC special briefing on mpox and the impact of conflict 1 February 2025. Related: mpox.
EU license for injectable cabotegravir/rilpivirine injections expanded to include adolescents >12 years old 31 January 2025. Related: Antiretrovirals.
US issues temporary waiver to re-enable PEPFAR 29 January 2025. Related: Treatment access.
IAS statement: PEPFAR freeze threatens millions of lives 25 January 2025. Related: Treatment access.
Trump bans travel for US government scientists, presentations restricted, documents disappearing 23 January 2025. Related: Treatment access, Treatment advocacy, Research studies.
Almost 1 in 5 people in Switzerland disconnected from HIV care over 10 years: only half reconnected and with advanced infection 22 January 2025. Related: Special reports, Treatment strategies.
BHIVA pregnancy guidelines online for comment: deadline 25 January 20 January 2025. Related: Pregnancy, Guidelines.
Detailed results from PALM007 study: no clinical impact of tecovirimat against mpox clade 1 6 January 2025. Related: mpox, IDWeek 2024.
Tecovirimat news continues: Japan approval includes mpox indication 2 January 2025. Related: mpox.
Looking back through 2024 and forward to 2025… 1 January 2025. Related: Editorial, Special reports.
i-Base appeal: Q&A services and the website in 2025 1 January 2025. Related: Editorial, Special reports.
ART pipeline 2025: exciting dual long-acting combinations and the challenge of generic dolutegravir 1 January 2025. Related: Special reports, Conference reports, Pipeline report, Antiretrovirals, HIV 17 Glasgow 2024.
Transient impact of lenacapavir against MDR HIV-2 without other active ART 1 January 2025. Related: Antiretrovirals, Treatment strategies, Virology, Drug resistance.
Lenacapavir submitted to the US FDA with an indication for HIV PrEP 1 January 2025. Related: Antiretrovirals, Treatment access, HIV prevention and transmission.
Chiva short films on children and HIV shortlisted for charity award 12 December 2024. Related: Paediatric care, Treatment advocacy, On the web.
HIVR4P 2024 conference resources now open access 12 December 2024. Related: Conference reports, On the web, R4P 2024 Lima.
Tecovirimat fails to show benefit in randomised STOMP study in mpox clade 2 10 December 2024. Related: mpox, Other news.
IAS-USA 2024 guidelines for HIV treatment and prevention: some differences to EACS and UK 5 December 2024. Related: Guidelines.
HTB news: i-Base changes during 2024 1 December 2024. Related: Editorial, Special reports.
Glasgow HIV Congress 2024: Introduction and links 26 November 2024. Related: Conference reports, Conference index, HIV 17 Glasgow 2024.
Once-weekly oral ART with islatravir plus lenacapavir sustains results to week 48 26 November 2024. Related: Conference reports, Antiretrovirals, HIV 17 Glasgow 2024.
EACS guidelines: New format and contents includes chemsex 26 November 2024. Related: Conference reports, Guidelines, HIV 17 Glasgow 2024.
Double dose start for oral PrEP in new EACS guidelines – rapid protection in two hours 26 November 2024. Related: Conference reports, Guidelines, HIV prevention and transmission, HIV 17 Glasgow 2024.
Future PrEP and new results on lenacapavir from PURPOSE 1 and 2 – does HIV exposure explain incident cases? 26 November 2024. Related: Conference reports, HIV prevention and transmission, HIV 17 Glasgow 2024.
Liverpool University Drug Interaction website recognised for global impact on research and care 26 November 2024. Related: Conference reports, PK and drug interactions, Treatment advocacy, HIV 17 Glasgow 2024.
HCV coinfection approaches zero in Spain: but cirrhosis and reinfection among gay men are still significant even with high rates of cure 26 November 2024. Related: Conference reports, Hepatitis coinfection, HIV 17 Glasgow 2024.